Back to the main directory
EarningsReview / Equity
- CLF, OUT1V, VALE, ACX by BNP Paribas Exane
- Acerinox - Recovery still postponed, but results holding steady by JB Capital Markets
- Vetropack profit warning - Read across by BNP Paribas Exane
- ACERINOX: RDOS. 3T’25 (ANÁLISIS BANCO SABADELL) by Sabadell
- European Food/HPC data (Nielsen, Sep’25): weather-driven categories better, beauty slower by BNP Paribas Exane
- Bloomberg reports plans for 20-30% dividend cut, no capital raise, no deals - a missed opportunity by BNP Paribas Exane
- Wavestone - Favorable turnaround expected in Q3 by MidCap Partners
- Ateme - Recovery scenario confirmed by MidCap Partners
- Amneal guides to launch Albuterol and Lanreotide soon; Negative readthrough for CIPLA and LUPIN by BNP Paribas Exane
- Nari Technology Co Ltd (600406 CH) by HSBC
- Tubacex - A weak quarter, waiting for the recovery by JB Capital Markets
- Keyence Corp (6861 JP) by HSBC
- Not a Halloween Fright but an Everyday Delight by BNP Paribas Exane
- ZWSOFT (688083 CH) by HSBC
- Still seeking steady footing in an uncertain macro by BNP Paribas Exane
- 中科创达（300496 CH） by HSBC
- 9M25: Apres le Call by BNP Paribas Exane
- 3Q25 Preview: Thoughts ahead of the print by BNP Paribas Exane
- Q3’25 No fireworks but not as bad as feared by BNP Paribas Exane
- Takeaways from 3Q25 results conference call by BNP Paribas Exane
- CaixaBank - Upbeat on growth and the NII for 2026; Reiterating Buy by JB Capital Markets
- 2QFY26: Result beat; ACEM’s capacity target lifted by BNP Paribas Exane
- Solid Q3 earnings and cash flow, with CVX outpacing Vs. consensus by BNP Paribas Exane
- Q325 results: Beat led by Colors by BNP Paribas Exane
- UNICAJA: 3Q’25 RESULTS (ANÁLISIS BANCO SABADELL) by Sabadell